Abstract
The tumors from approximately 50% of patients with breast cancer contained estrogen receptor (ER). ER appeared more often and at higher levels in the tumors of postmenopausal women. Eleven out of 12 patients who had multiple ER assays from various metastatic sites showed no significant discrepancies in ER values. ER level appears to decrease as the duration of metastatic cancer increase. Patients with ER in the tumor more frequently have bone metastases than those without ER. Visceral metastases occurred more often with ER negative patients and appeared to have a more malignant course with significant shorter survival.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cutler S. J., Ardyce J. A., Taylor S. G., 3rd Classification of patients with disseminated cancer of the breast. Cancer. 1969 Nov;24(5):861–869. doi: 10.1002/1097-0142(196911)24:5<861::aid-cncr2820240502>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- Godefroi V. C., Brooks S. C. Improved gel-filtration method for analysis of estrogen receptor binding. Anal Biochem. 1973 Feb;51(2):335–344. doi: 10.1016/0003-2697(73)90486-7. [DOI] [PubMed] [Google Scholar]
- Jensen E. V., DeSombre E. R. Estrogen-receptor interaction. Science. 1973 Oct 12;182(4108):126–134. doi: 10.1126/science.182.4108.126. [DOI] [PubMed] [Google Scholar]
- LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
- Truong H., Baulieu E. E. Interaction of uterus cytosol receptor with estradiol. Equilibrium and kinetic studies. Biochim Biophys Acta. 1971 Apr 20;237(1):167–172. doi: 10.1016/0304-4165(71)90045-6. [DOI] [PubMed] [Google Scholar]